Valeant Pharmaceuticals (VRX) reaches a revised agreement with Galderma which provides for a...

|About: Valeant Pharmaceuticals Int... (VRX)|By:, SA News Editor

Valeant Pharmaceuticals (VRX) reaches a revised agreement with Galderma which provides for a resolution of all claims asserted in Galderma's pending litigation relating to Valeant's acquisition of Medicis Pharmaceutical MRX. Under the terms of the agreement, Galderma will continue to supply VRX with Restylane and Perlane, which it currently supplies to (MRX). In addition, VRX will make an upfront payment to Galderma on sales of Sculptra, and will obtain North American rights to Emervel, which is designed to provide correction of facial lines, contouring and volume loss or lip enhancement.